HHS Pick, Former Eli Lilly Exec, Grilled over Zyprexa Scandal

Researchers Concerned About Over-Prescription of Risperdal

The most recent study published on the use of antipsychotics, such as Risperdal, Zyprexa and Seroquel, in children with ADHD has researchers concerned that there may be an over-prescription problem. The study published January 19, 2017 in The Canadian Journal of Psychiatry shows the same dramatic increase in use of antipsychotics prescribed off-label in children with ADHD, ages 1 […]
In The New York Times: “Side Effects May Include Lawsuits”

One of the most-read articles in The New York Times regarding pharmaceutical drug product liability and whistleblower lawsuits quotes Stephen Sheller. Side Effects May Include Lawsuits BY DUFF WILSON NEW YORK – FOR decades, antipsychotic drugs were a niche product. Today, they’re the top-selling class of pharmaceuticals in America, generating annual revenue of about $14.6 billion […]
$1.4 Billion Whistleblower Settlement
2009-01-15 Sheller, P.C.’s whistleblower/qui tam clients help U.S. government recover $1.4 billion record settlement and criminal fine in Eli Lilly & Company Zyprexa marketing case. [pdf-embedder url=”http://sheller.com/wp-content/uploads/2015/07/ShellerPC_ZyprexaNewsRelease_200901152.pdf”]
$1.4 Billion Settlement

Philadelphia Attorney Stephen Sheller’s Whistleblower Clients Help Government Recover $1.4 Billion Record Settlement and Criminal Fine in Eli Lilly & Company Zyprexa® Marketing Case Lead Attorney Filed Complaint in 2003 Representing Six Whistleblowers Pharmaceutical giant Eli Lilly & Company (“Lilly”) agreed to pay federal and state governments more than $1.4 billion in January 2009 to […]